Novel Modalities,
Transformative Outcomes

- Phase II program efficacious in Claudin 18.2 ultra-low expressors

- CD73 oral small molecule inhibitor with robust PoC data in reversing anti-PD-1 resistance

- Bispecific antibody targeting PD-L1/4-1BB overcoming liver toxicity

- First-in-class macrophage activator targeting CD24 expressing solid tumors

Our Approach

NextGen Novel Immuno-oncology and Targeted Drugs – Allowing Broad Proprietary Combinations

Tumor Microenvironment

Tumor Cell

  • ATN-022

    (Claudin 18.2 ADC)

    High-affinity antibody allowing the targeting of Claudin 18.2 low expressors
  • ATN-037

    (CD73 Small Molecule Inhibitor)

    Robust PoC data demonstrated ability in reversing anti-PD-1 resistance
  • ATN-101 (Xirestomig)

    (PD-L1/4-1BB Bispecific Antibody)

    Bispecific antibody targeting PD-L1/4-1BB overcoming liver toxicities
  • ATN-031

    (CD24 Monoclonal Antibody)

    Novel macrophage activator targeting CD24-expressing solid tumors

Clinical Pipeline

Validated and Transformational Clinical Programs

Assets
Target
(Modality)
IND
Phase I
Phase II
De-risked Programs Supported by PoC Data
Claudin 18.2
(ADC)
CLINCH
CD73
(Small Molecule)
STAMINA
Transformational Assets
PD-L1/4-1BB
(BsAb)
PROBE
CD24
(mAb)
PERFORM
Assets
Target
(Modality)
IND
Phase I
Phase II
De-risked Programs Supported by PoC Data

ATN-022

Claudin 18.2
(ADC)

CLINCH

ATN-037

CD73
(Small Molecule)

STAMINA
Transformational Assets

ATN-101
(Xirestomig)

PD-L1/4-1BB
(BsAb)

PROBE

ATN-031

CD24
(mAb)

PERFORM
Ongoing Trials

Strategic Pipeline with De-risked, Differentiated Programs and High-value Clinical Programs

ATN-022
ATN-037
ATN-101 (Xirestomig)
ATN-031
Target and Modality
Claudin 18.2 ADC
CD73 Small Molecule
PD-L1/4-1BB Bispecific Antibody
CD24 Monoclonal Antibody
Target Unmet Medical Needs
Claudin 18.2 Expressing tumors

(Claudin 18.2 Low/High Expression Gastric Cancer and Other Solid Tumors)
Checkpoint inhibitor (CPI)-resistant tumors

(Non-small Cell Lung Cancer and Melanoma)
Immune-responsive Tumors (e.g, Melanoma) and "Cold" Tumors

(e.g, Colorectal Cancer)
CD24 Expressing Tumors

(Breast Cancer, Ovarian Cancer, Small Cell Lung Cancer, Non-small Cell Lung Cancer, Liver Cancer, Bladder Cancer, B Cell Lymphoma)
Differentiation
High-affinity antibody allowing the targeting of Claudin 18.2 low expressors

Robust PoC data demonstrated ability in reversing prior anti-PD-1 resistance
Bispecific antibody targeting PD-L1/4-1BB overcoming liver toxicities
Novel macrophage activator targeting CD24 expressing solid tumors
ATN-022
Target and Modality
Claudin 18.2 ADC
Target Unmet Medical Needs
Claudin 18.2 Expressing tumors
(Claudin 18.2 Low/High Expression Gastric Cancer and Other Solid Tumors)
Differentiation
High-affinity antibody allowing the targeting of Claudin 18.2 low expressors
ATN-037
Target and Modality
CD73 Small Molecule
Target Unmet Medical Needs
Checkpoint inhibitor (CPI)-resistant tumors
(Non-small Cell Lung Cancer and Melanoma)
Differentiation
Robust PoC data demonstrated ability in reversing prior anti-PD-1 resistance
ATN-101 (Xirestomig)
Target and Modality
PD-L1/4-1BB Bispecific Antibody
Target Unmet Medical Needs
Immune-responsive Tumors (e.g, Melanoma)
and "Cold" Tumors (e.g, Colorectal Cancer)
Differentiation
Bispecific antibody targeting PD-L1/4-1BB overcoming liver toxicities
ATN-031
Target and Modality
CD24 Monoclonal Antibody
Target Unmet Medical Needs
CD24 Expressing Tumors
(Breast Cancer, Ovarian Cancer, Small Cell Lung Cancer, Non-small Cell Lung Cancer, Liver Cancer, Bladder Cancer, B Cell Lymphoma)
Differentiation
Novel macrophage activator targeting CD24 expressing solid tumors

Antennova Team

Jay Mei, M.D., Ph.D.
Founder / Interim CEO

Pennsylvania, US

Ariel Guo
Chief Operating Officer

Boston, MA, US

Donald Lung, JD, MBA
Interim Chief Financial Officer

Nadeem Mirza, M.D., MPH
Senior Clinical Expert

Houston, US

Sunny He
Senior Director, Clinical Operations

Jon Yau
Investor Relations Manager

Board of Directors

Jay Mei, M.D., Ph.D.
Executive Chairman of the Board

Learn more

Dr. Jay Mei has over 30 years of experience in the clinical research and development of oncology therapeutics globally and has successfully led the development of multiple oncology drugs throughout his career.

Prior to founding Antengene in 2017 and most recently Antennova, Dr. Mei served key global clinical development roles at Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), Novartis Oncology and Celgene (now part of Bristol-Myers Squibb) from 2001 to 2017.

Before joining industry, Dr. Mei spent almost eight years at the National Cancer Institute (NIH) after medical school and Ph.D trainings. Dr. Mei has been CEO and Chairman of Antengene Corporation, a HKEX listed company, since its establishment in 2017.

Donald Lung, JD, MBA
Executive Director

Learn more

Mr. Donald Lung was appointed as the Chief Financial Officer (CFO) of Antengene in June 2020 and has led the overall finance operations of Antengene since joining the company and will be the Interim CFO of Antennova.

Mr. Lung has over 16 years of experience in investment banking and public equities. From 2004 to 2008, Mr. Lung worked at Goldman Sachs (Asia) L.L.C. He was then engaged in the asset management business at Pine River Capital Management from 2012 to 2017 and at Myriad Asset Management Limited from 2017 to 2019. From 2019 to 2020, Mr. Lung worked as a Portfolio Manager at BFAM Partners (Hong Kong) Limited.

Mr. Lung received his Bachelor of Arts degree in economics and political science from Yale University in 2004. He also obtained a Master’s degree in Business Administration and a Juris Doctor degree from the Chinese University of Hong Kong, both in 2015.

Anne Altmeyer, Ph.D., MBA, MPH
Independent Non-executive Director

Learn more

Mr. Donald Lung was appointed as the Chief Financial Officer (CFO) of Antengene in June 2020 and has led the overall finance operations of Antengene since joining the company and will be the Interim CFO of Antennova.

Mr. Lung has over 16 years of experience in investment banking and public equities. From 2004 to 2008, Mr. Lung worked at Goldman Sachs (Asia) L.L.C. He was then engaged in the asset management business at Pine River Capital Management from 2012 to 2017 and at Myriad Asset Management Limited from 2017 to 2019. From 2019 to 2020, Mr. Lung worked as a Portfolio Manager at BFAM Partners (Hong Kong) Limited.

Mr. Lung received his Bachelor of Arts degree in economics and political science from Yale University in 2004. He also obtained a Master’s degree in Business Administration and a Juris Doctor degree from the Chinese University of Hong Kong, both in 2015.

Dr. Anne Altmeyer has 25 years of experience in developing and implementing strategies in R&D and Corporate Development in the pharmaceutical and biotech industries. She is currently the President, Chief Executive Officer, and member of the Board of Directors of TigaTx, Inc. She previously served as the Chief Business Officer at Sigilon Therapeutics, Inc. (acquired by Eli Lilly) and at Adicet Bio, Inc. Dr. Altmeyer also held roles of increasing responsibilities in large pharmaceutical organizations, including Vice President of Global Business Development at Baxalta (acquired by Shire); Vice President of Oncology Business Development and Companion Diagnostics at Novartis; Executive Director Project Leadership at Novartis; and Associate Director Project Management at Merck & Co.

Dr. Altmeyer is also an Independent Board Member of Corbus Pharmaceuticals.

Dr. Altmeyer received a Ph.D. in molecular immunology from Strasbourg University, France, and performed a postdoctoral fellowship at the New York University School of Medicine and was a research associate at Cornell University Medical College. Anne has also received an M.B.A. from Rutgers University and an M.P.H. from the University of Medicine and Dentistry of New Jersey.

Dr. Selwyn Ho currently serves as Chief Executive Officer of Medigene AG (FRA: MDG1), an early-stage immuno-oncology company focused on the development of T cell receptor guided therapies for solid tumors. In addition, he is an Executive in Residence at New Rhein Healthcare Investors, an investment firm applying a private equity business model to venture capital investing, and also as a Non-Executive Director at Immodulon Therapeutics Ltd, a private, late-stage clinical company developing a novel, broad spectrum immunomodulator, focused on treatment of pancreatic cancer, and as a Non-Executive Director for Peptomyc S.L, a private, clinical stage company focused on developing first-in-class mini-proteins targeting MYC, the most dysregulated oncogene in human cancers.

Prior to Medigene, Dr. Ho served as Chief Business Officer at Connect Biopharma (NASDAQ: CNTB), a global, clinical-stage biopharmaceutical company focused on developing innovative therapies that treat chronic inflammatory diseases. Dr. Ho has also held leadership positions at Dermira (acquired by Lilly in 2020), UCB, Allergan (Acquired by Abbvie in 2020), Novartis and AstraZeneca.

Dr. Ho received his medical degree (MB BS) and Bachelor of Science (BSc) in Pharmacology from Imperial College, University of London, and post-graduate qualifications (Dip Pharm Med) in Pharmaceutical Medicine from the Faculty of Pharmaceutical Physicians, Royal College of Physicians in the U.K.

Selwyn Ho, MB BS, B.Sc
Independent Non-executive Director

Learn more

Dr. Selwyn Ho currently serves as Chief Executive Officer of Medigene AG (FRA: MDG1), an early-stage immuno-oncology company focused on the development of T cell receptor guided therapies for solid tumors. In addition, he is an Executive in Residence at New Rhein Healthcare Investors, an investment firm applying a private equity business model to venture capital investing, and also as a Non-Executive Director at Immodulon Therapeutics Ltd, a private, late-stage clinical company developing a novel, broad spectrum immunomodulator, focused on treatment of pancreatic cancer, and as a Non-Executive Director for Peptomyc S.L, a private, clinical stage company focused on developing first-in-class mini-proteins targeting MYC, the most dysregulated oncogene in human cancers.

Prior to Medigene, Dr. Ho served as Chief Business Officer at Connect Biopharma (NASDAQ: CNTB), a global, clinical-stage biopharmaceutical company focused on developing innovative therapies that treat chronic inflammatory diseases. Dr. Ho has also held leadership positions at Dermira (acquired by Lilly in 2020), UCB, Allergan (Acquired by Abbvie in 2020), Novartis and AstraZeneca.

Dr. Ho received his medical degree (MB BS) and Bachelor of Science (BSc) in Pharmacology from Imperial College, University of London, and post-graduate qualifications (Dip Pharm Med) in Pharmaceutical Medicine from the Faculty of Pharmaceutical Physicians, Royal College of Physicians in the U.K.

Strategic Advisor

Shawn Leland, PharmD, RPh
Strategic Advisor

Learn more

Shawn M. Leland, PharmD, RPh is Chairman of Evexta Bio. Most recently, Shawn served as Interim CEO and a Board Director of Fore Bio where he helped lead the company’s $75M Series D financing. Previously, he was Founder, CEO and a Board Director of Elevation Oncology where he raised over $200M in capital, which included taking the company public. During his time at Elevation Oncology, Shawn led the licensing of a CLDN18.2 ADC from CSPC Pharmaceuticals and executed a strategic drug discovery partnership with Caris Life Sciences.

Prior to Elevation Oncology, Shawn held Head of Business Development roles at Verastem Oncology and Argos Therapeutics. Shawn started his career at Eli Lilly doing oncology search and evaluation along with medical affairs and spent time at ARIAD Pharmaceuticals working in medical affairs. During his tenure in the pharmaceutical and biotech industry, Shawn executed deals worth over $450M in upfront and milestone payments.

Shawn serves as a Strategic Advisor for multiple pharmaceutical, biotech and venture capital firms across the industry related to financing, partnering and R&D strategy. Shawn holds a PharmD from Albany College of Pharmacy.

News

Contact Us